Paper Details

  1. Home
  2. Paper Details

Effects of metaproterenol on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease.

Author: CabalL A, DurandM, HodgmanJ, LarrazabalC, LewisD, RamanathanR, SiassiB

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Metaproterenol improved lung function in newborn infants with chronic lung disease. The study showed that nebulized metaproterenol effectively reduced pulmonary resistance and improved oxygenation in preterm infants with respiratory issues.
Paper Details　
Original Abstract of the Article :
Changes in pulmonary resistance, dynamic compliance, tidal volume, and transcutaneous PO2 and PCO2 after nebulized administration of metaproterenol were evaluated in eight newborn infants (birth weight 650 to 1060 g, gestational age 25 to 28 weeks) with chronic lung disease receiving mechanical vent...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0022-3476(87)80302-5

データ提供：米国国立医学図書館（NLM）

Chronic Lung Disease in Infants: A Breath of Hope from Metaproterenol

Chronic lung disease in infants, a challenging condition often affecting premature babies, can feel like a heavy weight on their tiny lungs. This research explores the effects of metaproterenol, a bronchodilator, on pulmonary mechanics, oxygenation, and ventilation in infants with chronic lung disease. The authors conducted a study involving eight newborn infants with chronic lung disease requiring mechanical ventilation. They administered nebulized metaproterenol and monitored the infants' pulmonary function before and after treatment. Their findings reveal that metaproterenol significantly improved pulmonary compliance, tidal volume, and oxygenation, suggesting a potential benefit for these infants.

Metaproterenol: A Breath of Relief in the Desert of Chronic Lung Disease

The study suggests that metaproterenol, a bronchodilator, may offer a breath of relief for infants with chronic lung disease, improving their pulmonary function and oxygenation. This research highlights the potential of this medication to improve the breathing capabilities and overall well-being of infants struggling with this condition.

Navigating the Desert of Infant Lung Disease: Finding Effective Treatment Options

This research offers a glimmer of hope for infants facing the challenges of chronic lung disease. The study highlights the potential benefits of metaproterenol, suggesting that this medication may help to improve pulmonary function and oxygenation. Further research is needed to explore the long-term effects of metaproterenol and determine its optimal role in the management of chronic lung disease in infants.

Dr. Camel's Conclusion

The desert of chronic lung disease can be a challenging landscape for infants. This study offers a breath of hope, suggesting that metaproterenol, a bronchodilator, may improve pulmonary function and oxygenation. Continued research is essential to fully understand the potential of this medication and to develop effective treatment strategies for infants with this condition.

Date :
  1. Date Completed 1987-02-05
  2. Date Revised 2019-06-30
Further Info :

Pubmed ID

3794869

DOI: Digital Object Identifier

10.1016/s0022-3476(87)80302-5

Related Literature

Article Analysis
・Effects of metaproterenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.